S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
NASDAQ:NRXP

NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis

$3.04
+0.02 (+0.66%)
(As of 04/19/2024 ET)
Today's Range
$3.00
$3.25
50-Day Range
$3.02
$70.06
52-Week Range
$2.21
$12.00
Volume
233,600 shs
Average Volume
250,959 shs
Market Capitalization
$29.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NRXP stock logo

About NRx Pharmaceuticals Stock (NASDAQ:NRXP)

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression. The company has a partnership with Alvogen and Lotus to develop and commercialize NRX-101 for the suicidal bipolar depression treatment, as well as an agreement with Nephron Pharmaceuticals, Inc. to develop ketamine. The company was founded in 2015 and is based in Wilmington, Delaware.

NRXP Stock Price History

NRXP Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Rep. Raúl Grijalva announces cancer diagnosis
See More Headlines
Receive NRXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/21/2024
Next Earnings (Estimated)
5/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NRXP
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

Net Income
$-30,150,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.38) per share

Miscellaneous

Free Float
7,555,000
Market Cap
$29.09 million
Optionable
Optionable
Beta
1.02
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Jonathan C. Javitt M.D. (Age 67)
    M.P.H., Co-Founder, Chief Scientist Officer & Chairman
    Comp: $873.7k
  • Mr. Stephen H. Willard Esq. (Age 63)
    Acting Corporate Secretary, CEO & Director
    Comp: $501.19k
  • Dr. Riccardo Panicucci Ph.D. (Age 62)
    Chief Technology Officer
    Comp: $240k
  • Dr. Seth L. Van Voorhees Ph.D. (Age 63)
    Treasurer
    Comp: $399.96k
  • Mr. Richard Clavano Narido (Age 46)
    Interim CFO, Principal Financial Officer & Principal Accounting Officer
  • Suzanne Messere
    Investor Relations
  • Dr. Philip T. Lavin Ph.D. (Age 77)
    Chief Methodologist
  • Dr. Dennis K. McBride Ph.D.
    Chief Strategy Officer & Senior Scientist
  • Mr. Matthew Patrick Duffy (Age 61)
    Chief Business Officer

NRXP Stock Analysis - Frequently Asked Questions

How have NRXP shares performed in 2024?

NRx Pharmaceuticals' stock was trading at $46.00 on January 1st, 2024. Since then, NRXP stock has decreased by 93.4% and is now trading at $3.04.
View the best growth stocks for 2024 here
.

Are investors shorting NRx Pharmaceuticals?

NRx Pharmaceuticals saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 424,500 shares, a drop of 88.6% from the March 15th total of 3,710,000 shares. Based on an average trading volume of 159,600 shares, the days-to-cover ratio is currently 2.7 days. Currently, 6.7% of the shares of the stock are short sold.
View NRx Pharmaceuticals' Short Interest
.

When is NRx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our NRXP earnings forecast
.

What ETF holds NRx Pharmaceuticals' stock?

AdvisorShares Psychedelics ETF holds 70,285 shares of NRXP stock, representing 4.74% of its portfolio.

When did NRx Pharmaceuticals' stock split?

NRx Pharmaceuticals's stock reverse split on Tuesday, April 2nd 2024. The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What guidance has NRx Pharmaceuticals issued on next quarter's earnings?

NRx Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, March, 28th. The company provided earnings per share guidance of -0.400--0.400 for the period, compared to the consensus earnings per share estimate of -0.370. The company issued revenue guidance of -.

How do I buy shares of NRx Pharmaceuticals?

Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NRXP) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners